Evidence map›Paper›PMID 42352321›Full record

ReviewBiomolecules2026

The Immune-Chemokine Axis in Alzheimer's Disease: Roles of Adaptive Immune System in Neuroinflammation and Disease Progression.

José Joaquín Merino, José Julio Rodríguez-Arellano, Xavier Busquets, Isabel Álvarez-Vicente, María Eugenia Cabaña-Muñoz, Ana Isabel Flores, Adolfo Toledano Gasca

Abstract readReview
In one paragraph

Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

José Joaquín MerinoFacultad de Farmacia, Departamento de Farmacología, Farmacognosia y Botánica, Universidad Complutense de Madrid (UCM), 28040 Madrid, Spain.
José Julio Rodríguez-ArellanoFunctional Neuroanatomy Group, IKERBASQUE, Basque Foundation for Science, 48009 Bilbao, Spain.
Xavier BusquetsLaboratory of Molecular Cell Biomedicine, Department of Biology, Faculty of Medicine, University of the Balearic Islands, 07122 Palma de Mallorca, Spain.ORCID 0000-0003-1157-5590
Isabel Álvarez-VicenteInstituto Cajal, Consejo Superior de Investigaciones Científicas (CSIC), 28002 Madrid, Spain.ORCID 0000-0001-6796-809X
María Eugenia Cabaña-MuñozCentro de Rehabilitación Oral Multidisciplinaría (CIROM), 30001 Murcia, Spain.
Ana Isabel FloresGrupo de Medicina Regenerativa, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain.ORCID 0000-0002-5019-0434
Adolfo Toledano GascaInstituto Cajal, Consejo Superior de Investigaciones Científicas (CSIC), 28002 Madrid, Spain.ORCID 0000-0002-2274-5949

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder characterized by amyloid-β (Aβ) and the accumulation of tau in the brain, which triggers robust innate immune responses. Growing evidence indicates that neuroinflammation contributes to AD progression by overactivating microglia through the release of cytokines and chemokines. In general, chemokines can disrupt neuronal communication and promote blood-brain barrier permeability. Peripheral immune cells are mobilized into the brain by a gradient of chemokines. These processes link peripheral immune responses with substantial T-cell infiltration into the CNS parenchyma, leptomeninges and cerebrospinal fluid of both AD mice and AD patients. This finding underscores the relevance of the adaptive immune system, particularly T and B cells, in AD neuropathology. T-cell infiltration into the brain can influence amyloid clearance through chemokine signalling. However, chemokines play a critical role in AD by either promoting or suppressing disease progression. The infiltration of peripheral T and B cells into the brain parenchyma can exacerbate neuronal loss, yet it may also exert neuroprotective effects. Despite the presence of CD4

Indexed as

Adaptive ImmunityAlzheimer DiseaseChemokinesNeuroinflammatory DiseasesAmyloid beta-PeptidesAnimalsBrainDisease ProgressionHumansT-LymphocytesAmyloid beta-PeptidesChemokinesadaptive immune systemAlzheimer’s disease and neurodegenerative diseasesamyloid-βchemokinesCX3CR1/fractalkineCXCL0CXCR6glial activationimmunobiologyimmunologyinflammationinnate immune systemmonocytesneuroimmunologyneuroinflammationneurologyneuromodulationphotobiomodulationregulation of microglia activationT cellsTreg

Identifiers

PMID42352321
PMCPMC13297367

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.